Cctu
Clinical trials sponsored by Cctu, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could an immunotherapy drug tame liver cancer in hepatitis b patients? Results expected Dec 2026 (estimated)
- Aggressive chemo cocktail aims to wipe out rectal cancer before surgery Results expected Dec 2026 (estimated)
-
Could an immunotherapy drug tame liver cancer in hepatitis b patients?
Disease control OngoingThis phase 2 trial is testing the drug pembrolizumab in 30 people with advanced liver cancer linked to hepatitis B. Participants receive pembrolizumab every 3 weeks, and researchers will check how the tumors respond and how the immune system changes. The goal is to see if this im…
Phase 2 • Sponsor: CCTU • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Shorter radiation may be as safe for High-Risk prostate cancer
Disease control OngoingThis phase 2 trial tests whether a shorter, more intense radiation course (SBRT) causes fewer side effects than standard daily radiation (IMRT) in men with high-risk prostate cancer. Both groups also receive hormone therapy. The study will compare side effects, quality of life, a…
Phase 2 • Sponsor: CCTU • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Aggressive chemo cocktail aims to wipe out rectal cancer before surgery
Disease control OngoingThis phase 2 trial tests whether adding a stronger chemotherapy regimen (FOLFOXIRI) before the usual chemoradiation and surgery can improve outcomes for people with high-risk locally advanced rectal cancer. About 72 participants will be randomly assigned to either standard treatm…
Phase 2 • Sponsor: CCTU • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC